Alain Wynckel

Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience

Paul Coppo, Michaël Schwarzinger, M. Buffet et al. · PLoS ONE · 2010 · 407 citations · Full text

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

Pierre‐Louis Tharaux, Gilles Pialoux, Arthur Pavot et al. · The Lancet Respiratory Medicine · 2021 · 293 citations · Full text

Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center

Antoine Froissart, M. Buffet, Agnès Veyradier et al. · Critical Care Medicine · 2011 · 286 citations

Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients

Mikaël Ebbo, A. Grados, M. Samson et al. · PLoS ONE · 2017 · 239 citations · Full text

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura

Julie Gay, Lionel Galicier, François Provôt et al. · Blood · 2014 · 183 citations · Full text